Navigation Links
New fertility drug development techniques by Organon

In the 7th International Symposium on GnRH Analogs in Cancer and Human Reproduction, Organon presented new techniques of development of fertility drugs. Organon scientists have succeeded in customizing the follicle-stimulating hormone(FSH) molecule by adding a hybrid subunit, which extends FSH's active life. This was achieved through an international collaboration. This longer active life will mean fewer injections for the infertile patient, making the treatment less difficult// and more patient-friendly. The company indicated that a long-acting form of the genetically-produced fertility drug, Puregon(rFSH), has moved into the dose-finding phase of its development using the latest techniques of "knowledge driven drug development" (KD3). These new techniques model the drug's underlying mechanisms, and use that information to support decisions about doses, dose regimens and design of future trials.

Organon is also in the process of developing oral tablet formulation alternative to the injectable hormone hCG (human chorionic gonadotropin). hCG has been used, in the past 30 years, to make ovulation and final oocyte maturation take place with precise timing. However, it has only been available in the injectable form due to its high molecular weight. Now, scientists have identified through high-throughput screening, compounds similar to hCG, but with lower molecular weight. These compounds have been optimized with respect to potency, selectivity and safety. The new compound, an LH/hCG agonistic agent, interacts with the human LH receptor just like LH (and hCG). Scientists carried out pre-clinical tests of this LH agonist in rats and found that it induced ovulation after a single oral dose and that fertilization of the ovulated eggs resulted in the normal implantation of healthy embryos in these rats. The scientists at Organon who are also exploring the IVF cycle concluded that this oral compound could also play a role in other infertility indications or at othe r moments during and after an IVF cycle.


'"/>




Related medicine news :

1. Male infertility in relation to cancer
2. Male infertility in relation to pesticide
3. Infertility in relation with virus
4. Shapely sperm-a valuable indicator of fertility
5. Relief to pregnant women using fertility drugs
6. How to repeal male infertility?
7. Benefits in fertility procedures
8. Endometriosis connected to fertility
9. Mountain biking connected to infertility
10. Reduced fertility in men who mountain bike
11. Infertility may result from bone fragments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology: